Adlai Nortye (ANL) Competitors $2.00 +0.10 (+5.21%) Closing price 03:39 PM EasternExtended Trading$2.00 +0.00 (+0.05%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. ATAI, PVLA, AURA, CYRX, GLUE, PHAT, RNAC, TSVT, MNPR, and SEPNShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Atai Life Sciences (ATAI), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Cryoport (CYRX), Monte Rosa Therapeutics (GLUE), Phathom Pharmaceuticals (PHAT), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Monopar Therapeutics (MNPR), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Atai Life Sciences Palvella Therapeutics Aura Biosciences Cryoport Monte Rosa Therapeutics Phathom Pharmaceuticals Cartesian Therapeutics 2seventy bio Monopar Therapeutics Septerna Adlai Nortye (NASDAQ:ANL) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Do insiders and institutionals hold more shares of ANL or ATAI? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 31.2% of Atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, ANL or ATAI? Atai Life Sciences has lower revenue, but higher earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M14.75-$104.87MN/AN/AAtai Life Sciences$308K947.00-$40.22M-$0.93-1.57 Does the media favor ANL or ATAI? In the previous week, Adlai Nortye and Adlai Nortye both had 2 articles in the media. Adlai Nortye's average media sentiment score of 1.95 beat Atai Life Sciences' score of -0.83 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Atai Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Does the MarketBeat Community prefer ANL or ATAI? Atai Life Sciences received 326 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 66.53% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformAdlai NortyeOutperform Votes8100.00% Underperform VotesNo VotesAtai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% Which has more volatility & risk, ANL or ATAI? Adlai Nortye has a beta of -1.03, suggesting that its stock price is 203% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Do analysts rate ANL or ATAI? Adlai Nortye presently has a consensus price target of $9.00, indicating a potential upside of 350.23%. Atai Life Sciences has a consensus price target of $10.50, indicating a potential upside of 619.18%. Given Atai Life Sciences' higher probable upside, analysts plainly believe Atai Life Sciences is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ANL or ATAI more profitable? Adlai Nortye's return on equity of 0.00% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Atai Life Sciences N/A -65.75%-52.71% SummaryAtai Life Sciences beats Adlai Nortye on 7 of the 13 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.76M$6.68B$5.44B$7.81BDividend YieldN/A3.20%5.44%4.30%P/E RatioN/A7.1422.1418.36Price / Sales14.75238.91389.71101.37Price / CashN/A65.6738.2034.62Price / BookN/A6.266.664.18Net Income-$104.87M$142.48M$3.21B$247.71M7 Day Performance16.90%7.91%5.83%6.45%1 Month Performance-12.90%-6.03%-4.31%-3.14%1 Year Performance-85.15%-0.96%17.83%5.40% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye2.0463 of 5 stars$2.00+5.2%$9.00+350.2%-86.0%$73.76M$5M0.00127Positive NewsGap UpHigh Trading VolumeATAIAtai Life Sciences2.5375 of 5 stars$1.42-3.4%$10.50+639.4%-18.2%$283.69M$308,000.00-1.7580PVLAPalvella Therapeutics3.4797 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AHigh Trading VolumeAURAAura Biosciences2.3075 of 5 stars$5.57+3.9%$22.75+308.4%-22.3%$279.75MN/A-3.2250Positive NewsCYRXCryoport2.4985 of 5 stars$5.52-0.5%$11.67+111.4%-63.7%$275.50M$228.39M-1.631,020Gap DownGLUEMonte Rosa Therapeutics2.9588 of 5 stars$4.46-2.0%$15.50+247.5%-4.6%$274.34M$75.62M-2.4490Positive NewsPHATPhathom Pharmaceuticals3.5849 of 5 stars$3.90-3.2%$21.83+459.8%-54.8%$271.58M$55.25M-0.69110Upcoming EarningsRNACCartesian Therapeutics1.8494 of 5 stars$10.34-1.5%$42.14+307.6%-41.8%$267.88M$38.91M-0.2064TSVT2seventy bio2.2607 of 5 stars$4.99+0.2%$5.60+12.2%+16.9%$261.17M$37.86M-2.68440Upcoming EarningsAnalyst ForecastMNPRMonopar Therapeutics1.0698 of 5 stars$42.71+7.9%$55.33+29.6%+1,256.8%$261.09MN/A-21.6810Gap DownSEPNSepterna2.2295 of 5 stars$5.87-0.5%$33.00+462.2%N/A$260.88M$1.08M0.00N/ALockup ExpirationPositive News Related Companies and Tools Related Companies Atai Life Sciences Alternatives Palvella Therapeutics Alternatives Aura Biosciences Alternatives Cryoport Alternatives Monte Rosa Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Cartesian Therapeutics Alternatives 2seventy bio Alternatives Monopar Therapeutics Alternatives Septerna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
